Physician profile
James Hall
NPI 1073533956
$1,812.19
in general payments reported to CMS, 2019-2025
23 companies · $84.56 in 2025
The $84.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $487 · 2021: $459 · 2022: $256 · 2023: $95.33 · 2024: $91.24 · 2025: $84.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $440.41 | 2019-2022 | |
| Pfizer INC. | $200.62 | 2020-2025 | |
| Novo Nordisk INC | $177.41 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $122.25 | 2019-2021 | |
| Lilly USA, LLC | $98.87 | 2020-2024 | Mounjaro, Zepbound |
| Amgen INC. | $86.65 | 2020 | |
| Merck Sharp & Dohme LLC | $74.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $72.53 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $71.26 | 2021-2022 | |
| Amarin Pharma, INC. | $67.18 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.88 | 2020 | |
| Currax Pharmaceuticals LLC | $45.94 | 2021 | |
| Genentech USA, INC. | $43.44 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.82 | 2022 | |
| Abbvie INC. | $42.46 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.74 | 2021-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $24.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.39 | 2019 | |
| Inspire Medical Systems, INC. | $21.56 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $21.30 | 2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $19.21 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.86 | 2022 | |
| Eisai INC. | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.